Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte

  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités

2 results

  • Topics : Mental disorders and behavioural conditions
  • Active substance : valproate de sodium
Filter
Topic
  • Diseases and conditions (2)
  • Plus ...
    • Mental disorders and behavioural conditions (2)
    • Plus ...
      • Substance-related disorders (1)
      • Disorders of psychological development (1)
    • Nervous system diseases (1)
    • Plus ...
      • Central nervous system diseases (1)
    • Pain - Inflammation (1)
  • Economics and public health (1)
  • Plus ...
    • Organisation of care (1)
    • Screening, prevention (1)
  • Population groups (1)
  • Plus ...
    • Paediatrics (1)
Content type
  • Practice Guidelines and Other Guides (2)
  • Plus ...
    • Practice guidelines (2)
Language
  • Français (2)
Active substance
  • alcool (2)
  • amitriptyline (1)
  • aspirine (1)
  • naratriptan (1)
  • nicotine (1)
  • sodium (1)
  • sumatriptan (1)
  • valproate de sodium (2)
  • zolmitriptan (1)
 More filter Other Filter Icon
Search Export

Practice guidelines and other guides - 2 results

  • Neurodevelopmental disorders Detection and referral of at-risk children

    Practice guidelines - Posted on 17/3/2020 - Mis à jour le 19/3/2020
    Download abstract
    Add to my selection

  • Chronic daily headache (CDH) – Diagnosis, medication overuse, and management

    Practice guidelines - Posted on 1/9/2004 - Mis à jour le 19/7/2006
    Download abstract
    Add to my selection

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
E2cdA0YzcjuNBJWY